MARKET

SLRX

SLRX

Salarius Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6700
+0.0550
+8.94%
After Hours: 0.6800 +0.01 +1.49% 17:15 03/27 EDT
OPEN
0.6457
PREV CLOSE
0.6150
HIGH
0.6980
LOW
0.6050
VOLUME
96.40K
TURNOVER
--
52 WEEK HIGH
24.45
52 WEEK LOW
0.5552
MARKET CAP
9.99M
P/E (TTM)
-0.1579
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SLRX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SLRX stock price target is 9.00 with a high estimate of 9.00 and a low estimate of 9.00.

EPS

SLRX News

More
  • Salarius Pharmaceuticals EPS misses by $0.14, beats on revenue
  • seekingalpha · 5d ago
  • Salarius Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results
  • GlobeNewswire · 5d ago
  • The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
  • Benzinga · 03/13 11:52
  • Salarius Announces Allowance of New European Patent Covering Seclidemstat
  • GlobeNewswire · 03/04 13:00

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About SLRX

Salarius Pharmaceuticals, Inc., formerly Flex Pharma, Inc., is a clinical-stage oncology company. The Company is developing targeted therapies to treat pediatric and other cancers, including solid tumors. The Company is targeting the epigenetic causes of cancers and is developing treatments for patients. The Company’s lead candidate, Seclidemstat, is a reversible lysine specific histone demethylase 1 (LSD1) inhibitor. Seclidemstat is in phase I clinical study for treating Ewing sarcoma. Seclidemstat inhibits LSD1's demethylation and scaffolding properties, representing a therapeutic option for patients who need it. The Company is also developing Seclidemstat for a number of cancers with unmet need, with a clinical study in solid tumors including, prostate, breast and ovarian cancers.
More

Webull offers kinds of Salarius Pharmaceuticals Inc stock information, including NASDAQ:SLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLRX stock news, and many more online research tools to help you make informed decisions.